Aprotinin	B:C0003641
vs.	O
tranexamic	O
acid	I:C0040613
in	O
isolated	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
surgery	I:C0010055
:	O
A	O
multicentre	O
observational	I:C1518527
study	I:C1518527
.	O

Aprotinin	O
vs.	O
tranexamic	B:C0040613
acid	I:C0040613
in	O
isolated	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
surgery	I:C0010055
:	O
A	O
multicentre	O
observational	I:C1518527
study	I:C1518527
.	O

Aprotinin	O
vs.	O
tranexamic	O
acid	I:C0040613
in	O
isolated	O
coronary	B:C0010055
artery	I:C0010055
bypass	I:C0010055
surgery	I:C0010055
:	O
A	O
multicentre	O
observational	I:C1518527
study	I:C1518527
.	O

Aprotinin	O
vs.	O
tranexamic	O
acid	I:C0040613
in	O
isolated	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
surgery	I:C0010055
:	O
A	O
multicentre	B:C1518527
observational	I:C1518527
study	I:C1518527
.	O

Aprotinin	B:C0003641
appears	O
to	O
be	O
more	O
efficacious	O
than	O
lysine	O
analogues	O
to	O
reduce	O
bleeding	O
and	O
transfusion	O
of	I:C0371802
blood	I:C0371802
products	I:C0371802
in	O
high	O
-	I:C0243095
transfusion	I:C0243095
-	I:C0243095
risk	I:C0243095
cardiac	O
surgical	O
patients	O
.	O

Aprotinin	O
appears	O
to	O
be	O
more	O
efficacious	O
than	O
lysine	O
analogues	O
to	O
reduce	O
bleeding	B:C0019080
and	O
transfusion	O
of	I:C0371802
blood	I:C0371802
products	I:C0371802
in	O
high	O
-	I:C0243095
transfusion	I:C0243095
-	I:C0243095
risk	I:C0243095
cardiac	O
surgical	O
patients	O
.	O

Aprotinin	O
appears	O
to	O
be	O
more	O
efficacious	O
than	O
lysine	O
analogues	O
to	O
reduce	O
bleeding	O
and	O
transfusion	B:C0371802
of	I:C0371802
blood	I:C0371802
products	I:C0371802
in	O
high	O
-	I:C0243095
transfusion	I:C0243095
-	I:C0243095
risk	I:C0243095
cardiac	O
surgical	O
patients	O
.	O

Aprotinin	O
appears	O
to	O
be	O
more	O
efficacious	O
than	O
lysine	O
analogues	O
to	O
reduce	O
bleeding	O
and	O
transfusion	O
of	I:C0371802
blood	I:C0371802
products	I:C0371802
in	O
high	B:C0243095
-	I:C0243095
transfusion	I:C0243095
-	I:C0243095
risk	I:C0243095
cardiac	O
surgical	O
patients	O
.	O

Aprotinin	O
appears	O
to	O
be	O
more	O
efficacious	O
than	O
lysine	O
analogues	O
to	O
reduce	O
bleeding	O
and	O
transfusion	O
of	I:C0371802
blood	I:C0371802
products	I:C0371802
in	O
high	O
-	I:C0243095
transfusion	I:C0243095
-	I:C0243095
risk	I:C0243095
cardiac	B:C0018787
surgical	O
patients	O
.	O

However	O
,	O
in	O
isolated	B:C0010055
coronary	I:C0010055
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
(	I:C0010055
CABG	I:C0010055
)	I:C0010055
surgery	I:C0010055
,	O
the	O
results	O
from	O
head	O
-	I:C0008976
to	I:C0008976
-	I:C0008976
head	I:C0008976
trials	I:C0008976
remain	O
less	O
conclusive	O
.	O

However	O
,	O
in	O
isolated	O
coronary	I:C0010055
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
(	I:C0010055
CABG	I:C0010055
)	I:C0010055
surgery	I:C0010055
,	O
the	O
results	O
from	O
head	B:C0008976
-	I:C0008976
to	I:C0008976
-	I:C0008976
head	I:C0008976
trials	I:C0008976
remain	O
less	O
conclusive	O
.	O

Our	O
objective	O
was	O
to	O
compare	B:C1707887
the	I:C1707887
efficacies	I:C1707887
and	O
safety	O
of	O
aprotinin	O
and	O
tranexamic	O
acid	I:C0040613
(	O
tranexamic	O
acid	I:C0040613
)	O
in	O
patients	O
undergoing	O
isolated	O
on	O
-	O
pump	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

Our	O
objective	O
was	O
to	O
compare	O
the	I:C1707887
efficacies	I:C1707887
and	O
safety	B:C1705187
of	O
aprotinin	O
and	O
tranexamic	O
acid	I:C0040613
(	O
tranexamic	O
acid	I:C0040613
)	O
in	O
patients	O
undergoing	O
isolated	O
on	O
-	O
pump	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

Our	O
objective	O
was	O
to	O
compare	O
the	I:C1707887
efficacies	I:C1707887
and	O
safety	O
of	O
aprotinin	B:C0003641
and	O
tranexamic	O
acid	I:C0040613
(	O
tranexamic	O
acid	I:C0040613
)	O
in	O
patients	O
undergoing	O
isolated	O
on	O
-	O
pump	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

Our	O
objective	O
was	O
to	O
compare	O
the	I:C1707887
efficacies	I:C1707887
and	O
safety	O
of	O
aprotinin	O
and	O
tranexamic	B:C0040613
acid	I:C0040613
(	O
tranexamic	O
acid	I:C0040613
)	O
in	O
patients	O
undergoing	O
isolated	O
on	O
-	O
pump	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

Our	O
objective	O
was	O
to	O
compare	O
the	I:C1707887
efficacies	I:C1707887
and	O
safety	O
of	O
aprotinin	O
and	O
tranexamic	O
acid	I:C0040613
(	O
tranexamic	B:C0040613
acid	I:C0040613
)	O
in	O
patients	O
undergoing	O
isolated	O
on	O
-	O
pump	O
coronary	O
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

Our	O
objective	O
was	O
to	O
compare	O
the	I:C1707887
efficacies	I:C1707887
and	O
safety	O
of	O
aprotinin	O
and	O
tranexamic	O
acid	I:C0040613
(	O
tranexamic	O
acid	I:C0040613
)	O
in	O
patients	O
undergoing	O
isolated	O
on	O
-	O
pump	O
coronary	B:C0010055
artery	I:C0010055
bypass	I:C0010055
graft	I:C0010055
.	O

A	O
multicentre	O
before	B:C1516606
-	I:C1516606
and	I:C1516606
-	I:C1516606
after	I:C1516606
study	I:C1516606
pooling	I:C1516606
individual	I:C1516606
data	I:C1516606
from	O
published	O
trials	I:C1096775
and	O
unpublished	O
data	O
from	O
three	O
other	O
databases	O
.	O

A	O
multicentre	O
before	O
-	I:C1516606
and	I:C1516606
-	I:C1516606
after	I:C1516606
study	I:C1516606
pooling	I:C1516606
individual	I:C1516606
data	I:C1516606
from	O
published	B:C1096775
trials	I:C1096775
and	O
unpublished	O
data	O
from	O
three	O
other	O
databases	O
.	O

A	O
multicentre	O
before	O
-	I:C1516606
and	I:C1516606
-	I:C1516606
after	I:C1516606
study	I:C1516606
pooling	I:C1516606
individual	I:C1516606
data	I:C1516606
from	O
published	O
trials	I:C1096775
and	O
unpublished	O
data	O
from	O
three	O
other	O
databases	B:C0242356
.	O

Four	O
tertiary	B:C0337954
care	I:C0337954
teaching	I:C0337954
hospitals	I:C0337954
(	O
Haut	O
-	O
Lévêque	O
Hospital	O
in	O
Bordeaux	O
,	O
Pitié	O
-	O
Salpêtrière	O
Hospital	O
and	O
Bichat	O
-	I:C0019994
Claude	I:C0019994
Bernard	I:C0019994
Hospital	I:C0019994
in	O
Paris	O
,	O
and	O
Laennec	O
Hospital	I:C0019994
in	O
Nantes	O
)	O
.	O

Four	O
tertiary	O
care	I:C0337954
teaching	I:C0337954
hospitals	I:C0337954
(	O
Haut	O
-	O
Lévêque	O
Hospital	O
in	O
Bordeaux	O
,	O
Pitié	O
-	O
Salpêtrière	O
Hospital	O
and	O
Bichat	B:C0019994
-	I:C0019994
Claude	I:C0019994
Bernard	I:C0019994
Hospital	I:C0019994
in	O
Paris	O
,	O
and	O
Laennec	O
Hospital	I:C0019994
in	O
Nantes	O
)	O
.	O

Four	O
tertiary	O
care	I:C0337954
teaching	I:C0337954
hospitals	I:C0337954
(	O
Haut	O
-	O
Lévêque	O
Hospital	O
in	O
Bordeaux	O
,	O
Pitié	O
-	O
Salpêtrière	O
Hospital	O
and	O
Bichat	O
-	I:C0019994
Claude	I:C0019994
Bernard	I:C0019994
Hospital	I:C0019994
in	O
Paris	B:C0030561
,	O
and	O
Laennec	O
Hospital	I:C0019994
in	O
Nantes	O
)	O
.	O

Four	O
tertiary	O
care	I:C0337954
teaching	I:C0337954
hospitals	I:C0337954
(	O
Haut	O
-	O
Lévêque	O
Hospital	O
in	O
Bordeaux	O
,	O
Pitié	O
-	O
Salpêtrière	O
Hospital	O
and	O
Bichat	O
-	I:C0019994
Claude	I:C0019994
Bernard	I:C0019994
Hospital	I:C0019994
in	O
Paris	O
,	O
and	O
Laennec	B:C0019994
Hospital	I:C0019994
in	O
Nantes	O
)	O
.	O

We	O
included	O
data	O
of	O
2496	O
isolated	O
on	O
-	O
pump	O
CABG	B:C0010055
surgery	I:C0010055
patients	O
who	O
received	O
either	O
aprotinin	O
between	O
November	O
2003	O
and	O
May	O
2008	O
(	O
n	O
=	O
1267	O
)	O
or	O
tranexamic	O
acid	I:C0003641
between	O
November	O
2007	O
and	O
November	O
2013	O
(	O
n	O
=	O
1229	O
)	O
.	O

We	O
included	O
data	O
of	O
2496	O
isolated	O
on	O
-	O
pump	O
CABG	O
surgery	I:C0010055
patients	O
who	O
received	O
either	O
aprotinin	B:C0003641
between	O
November	O
2003	O
and	O
May	O
2008	O
(	O
n	O
=	O
1267	O
)	O
or	O
tranexamic	O
acid	I:C0003641
between	O
November	O
2007	O
and	O
November	O
2013	O
(	O
n	O
=	O
1229	O
)	O
.	O

We	O
included	O
data	O
of	O
2496	O
isolated	O
on	O
-	O
pump	O
CABG	O
surgery	I:C0010055
patients	O
who	O
received	O
either	O
aprotinin	O
between	O
November	O
2003	O
and	O
May	O
2008	O
(	O
n	O
=	O
1267	O
)	O
or	O
tranexamic	B:C0003641
acid	I:C0003641
between	O
November	O
2007	O
and	O
November	O
2013	O
(	O
n	O
=	O
1229	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
total	O
blood	B:C0032788
loss	I:C0032788
within	O
24	O
h	O
after	O
operation	O
.	O

The	O
primary	O
outcome	O
was	O
total	O
blood	O
loss	I:C0032788
within	O
24	O
h	O
after	O
operation	B:C0543467
.	O

Secondary	O
outcomes	O
were	O
transfusion	B:C0371802
of	I:C0371802
blood	I:C0371802
products	I:C0371802
,	O
reoperation	O
for	I:C0035110
bleeding	I:C0035110
,	O
renal	O
replacement	I:C0206074
therapy	I:C0206074
,	O
ICU	O
length	O
of	O
stay	O
and	O
in	O
-	O
hospital	O
mortality	O
.	O

Secondary	O
outcomes	O
were	O
transfusion	O
of	I:C0371802
blood	I:C0371802
products	I:C0371802
,	O
reoperation	B:C0035110
for	I:C0035110
bleeding	I:C0035110
,	O
renal	O
replacement	I:C0206074
therapy	I:C0206074
,	O
ICU	O
length	O
of	O
stay	O
and	O
in	O
-	O
hospital	O
mortality	O
.	O

Secondary	O
outcomes	O
were	O
transfusion	O
of	I:C0371802
blood	I:C0371802
products	I:C0371802
,	O
reoperation	O
for	I:C0035110
bleeding	I:C0035110
,	O
renal	B:C0206074
replacement	I:C0206074
therapy	I:C0206074
,	O
ICU	O
length	O
of	O
stay	O
and	O
in	O
-	O
hospital	O
mortality	O
.	O

Adjusted	O
mean	O
(	O
SEM	O
)	O
24-h	O
blood	B:C0032788
loss	I:C0032788
after	I:C0032788
surgery	I:C0032788
[	O
483	O
(	O
11	O
)	O
vs.	O
634	O
(	O
11	O
)	O
ml	O
,	O
P	O
<	O
0.0001	O
]	O
and	O
the	O
proportion	O
of	O
patients	O
requiring	O
intraoperative	I:C4075673
blood	I:C4075673
product	I:C4075673
transfusion	I:C4075673
(	O
32.7	O
vs.	O
46.5	O
%	O
,	O
P	O
=	O
0.01	O
)	O
were	O
lower	O
in	O
aprotinin	O
-	O
treated	O
patients	O
.	O

Adjusted	O
mean	O
(	O
SEM	O
)	O
24-h	O
blood	O
loss	I:C0032788
after	I:C0032788
surgery	I:C0032788
[	O
483	O
(	O
11	O
)	O
vs.	O
634	O
(	O
11	O
)	O
ml	O
,	O
P	O
<	O
0.0001	O
]	O
and	O
the	O
proportion	O
of	O
patients	O
requiring	B:C4075673
intraoperative	I:C4075673
blood	I:C4075673
product	I:C4075673
transfusion	I:C4075673
(	O
32.7	O
vs.	O
46.5	O
%	O
,	O
P	O
=	O
0.01	O
)	O
were	O
lower	O
in	O
aprotinin	O
-	O
treated	O
patients	O
.	O

Adjusted	O
mean	O
(	O
SEM	O
)	O
24-h	O
blood	O
loss	I:C0032788
after	I:C0032788
surgery	I:C0032788
[	O
483	O
(	O
11	O
)	O
vs.	O
634	O
(	O
11	O
)	O
ml	O
,	O
P	O
<	O
0.0001	O
]	O
and	O
the	O
proportion	O
of	O
patients	O
requiring	O
intraoperative	I:C4075673
blood	I:C4075673
product	I:C4075673
transfusion	I:C4075673
(	O
32.7	O
vs.	O
46.5	O
%	O
,	O
P	O
=	O
0.01	O
)	O
were	O
lower	O
in	O
aprotinin	B:C0003641
-	O
treated	O
patients	O
.	O

No	O
difference	O
was	O
observed	O
with	O
regard	O
to	O
reoperations	B:C0035110
for	I:C0035110
bleeding	I:C0035110
,	O
renal	O
replacement	I:C0206074
therapy	I:C0206074
and	O
in	O
-	O
hospital	O
mortality	O
.	O

No	O
difference	O
was	O
observed	O
with	O
regard	O
to	O
reoperations	O
for	I:C0035110
bleeding	I:C0035110
,	O
renal	B:C0206074
replacement	I:C0206074
therapy	I:C0206074
and	O
in	O
-	O
hospital	O
mortality	O
.	O

However	O
,	O
patients	O
receiving	O
aprotinin	B:C0003641
had	O
a	O
significantly	O
shorter	O
adjusted	O
ICU	O
length	O
of	O
stay	O
.	O

In	O
patients	O
undergoing	O
isolated	B:C0010055
CABG	I:C0010055
,	O
aprotinin	O
was	O
more	O
effective	O
than	O
tranexamic	O
acid	I:C0003641
in	O
reducing	O
postoperative	O
blood	I:C0032788
loss	I:C0032788
,	O
and	O
no	O
safety	O
concerns	O
were	O
identified	O
.	O

In	O
patients	O
undergoing	O
isolated	O
CABG	I:C0010055
,	O
aprotinin	B:C0003641
was	O
more	O
effective	O
than	O
tranexamic	O
acid	I:C0003641
in	O
reducing	O
postoperative	O
blood	I:C0032788
loss	I:C0032788
,	O
and	O
no	O
safety	O
concerns	O
were	O
identified	O
.	O

In	O
patients	O
undergoing	O
isolated	O
CABG	I:C0010055
,	O
aprotinin	O
was	O
more	O
effective	O
than	O
tranexamic	B:C0003641
acid	I:C0003641
in	O
reducing	O
postoperative	O
blood	I:C0032788
loss	I:C0032788
,	O
and	O
no	O
safety	O
concerns	O
were	O
identified	O
.	O

In	O
patients	O
undergoing	O
isolated	O
CABG	I:C0010055
,	O
aprotinin	O
was	O
more	O
effective	O
than	O
tranexamic	O
acid	I:C0003641
in	O
reducing	O
postoperative	B:C0032788
blood	I:C0032788
loss	I:C0032788
,	O
and	O
no	O
safety	O
concerns	O
were	O
identified	O
.	O

The	O
benefits	O
of	O
aprotinin	B:C0003641
should	O
be	O
considered	O
when	O
evaluating	O
the	O
risk	O
of	O
major	O
blood	I:C0019080
loss	I:C0019080
and	O
transfusion	O
in	O
patients	O
scheduled	O
for	O
isolated	O
CABG	O
surgery	I:C0010055
.	O

The	O
benefits	O
of	O
aprotinin	O
should	O
be	O
considered	O
when	O
evaluating	O
the	O
risk	O
of	O
major	B:C0019080
blood	I:C0019080
loss	I:C0019080
and	O
transfusion	O
in	O
patients	O
scheduled	O
for	O
isolated	O
CABG	O
surgery	I:C0010055
.	O

The	O
benefits	O
of	O
aprotinin	O
should	O
be	O
considered	O
when	O
evaluating	O
the	O
risk	O
of	O
major	O
blood	I:C0019080
loss	I:C0019080
and	O
transfusion	B:C0005841
in	O
patients	O
scheduled	O
for	O
isolated	O
CABG	O
surgery	I:C0010055
.	O

The	O
benefits	O
of	O
aprotinin	O
should	O
be	O
considered	O
when	O
evaluating	O
the	O
risk	O
of	O
major	O
blood	I:C0019080
loss	I:C0019080
and	O
transfusion	O
in	O
patients	O
scheduled	O
for	O
isolated	O
CABG	B:C0010055
surgery	I:C0010055
.	O

